Education
About Us
Working with TipRanks
Follow Us
Exelixis (EXEL)
:EXEL
EXEL Analyst Ratings
Moderate Buy
10 Buy
8 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
EXEL Stock 12 Month Forecast
Average Price Target
$43.57
▲(8.90% Upside)
| Highest Price Target$56.00 | Average Price Target$43.57 | Lowest Price Target$35.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
William Blair
―
Buy
―
Reiterated
09/30/25
Optimistic Buy Rating for Exelixis Amid Promising Phase III Trial Results for ZanzalintinibPhase III in CRC at We expect detailed results from the Phase III STELLAR-303 trial to be presented on Oncology (ESMO) annual meeting, taking place October 17-21 in Berlin. The trial is exploring zanzalintinib in combination with Tecentriq versus Stivarga in third-line and later patients with MSS/MSI-low metastatic colorectal cancer (mCRC). Top-line results from STELLAR-303 were announced in June and highlighted that the trial met one of the dual primary endpoints of overall survival in the intent-to-treat population (both with and without liver metastases). The trial is continuing to evaluate the other dual primary endpoint of overall survival in patients without liver metastases.
UBS
$38→$35
Hold
-12.52%
Downside
Reiterated
09/22/25
Morgan Stanley
$46→$50
Buy
24.97%
Upside
Reiterated
09/17/25
Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX), Repligen (NASDAQ: RGEN) and Exelixis (NASDAQ: EXEL)We model ~$4.7bn in unadjusted peak sales (~$2.3bn in risk-adjusted sales) vs. more conservative Street estimates of ~$2.7bn in unadjusted peak sales by 2035 (risk-adjusted sales of ~$1.5bn). Exelixis has projected a peak $5bn aspirational forecast for unadjusted zanza net product revenues in 2033.
Goldman Sachs
$39.04
Buy
-2.42%
Downside
Initiated
09/17/25
H.C. Wainwright
$46
Buy
14.97%
Upside
Reiterated
09/17/25
Barclays
$40
Hold
-0.02%
Downside
Initiated
09/16/25
Citi
$56
Buy
39.97%
Upside
Reiterated
09/04/25
Exelixis's Promising Growth Potential and Strategic Expansion Justify Buy RatingWe hosted Exelixis management for a fireside chat at our Biopharma Conference, where we discussed the history of cabozantinib development, including its past, present, and future growth trajectories in its leading indication of renal cell carcinoma (RCC), where mgt estimates it currently has 25% market share in the first-line setting and 45% share in the second-line. The next chapter of growth is expected to be driven by the newly launched neuroendocrine tumor (NET) indication, which has not really yet been factored into the company’s revenue guidance raise for FY25. As for main pipeline asset zanzalintinib, which was designed as an improvement over Cabometyx, mgt continues to execute on clinical trials to bring the follow-on drug into new indications where cabo is not currently approved to avoid self-cannibalization of revenues.
TD Cowen
$44
Buy
9.97%
Upside
Reiterated
07/29/25
Guggenheim
$45
Buy
12.47%
Upside
Reiterated
07/29/25
Wells Fargo
$36
Hold
-10.02%
Downside
Reiterated
07/29/25
RBC Capital
$50→$45
Hold
12.47%
Upside
Reiterated
07/29/25
Bank of America Securities
―
Hold
―
Reiterated
07/29/25
Leerink Partners
$39→$38
Hold
-5.02%
Downside
Reiterated
07/29/25
Oppenheimer
$36
Hold
-10.02%
Downside
Reiterated
07/29/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
William Blair
―
Buy
―
Reiterated
09/30/25
Optimistic Buy Rating for Exelixis Amid Promising Phase III Trial Results for ZanzalintinibPhase III in CRC at We expect detailed results from the Phase III STELLAR-303 trial to be presented on Oncology (ESMO) annual meeting, taking place October 17-21 in Berlin. The trial is exploring zanzalintinib in combination with Tecentriq versus Stivarga in third-line and later patients with MSS/MSI-low metastatic colorectal cancer (mCRC). Top-line results from STELLAR-303 were announced in June and highlighted that the trial met one of the dual primary endpoints of overall survival in the intent-to-treat population (both with and without liver metastases). The trial is continuing to evaluate the other dual primary endpoint of overall survival in patients without liver metastases.
UBS
$38→$35
Hold
-12.52%
Downside
Reiterated
09/22/25
Morgan Stanley
$46→$50
Buy
24.97%
Upside
Reiterated
09/17/25
Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX), Repligen (NASDAQ: RGEN) and Exelixis (NASDAQ: EXEL)We model ~$4.7bn in unadjusted peak sales (~$2.3bn in risk-adjusted sales) vs. more conservative Street estimates of ~$2.7bn in unadjusted peak sales by 2035 (risk-adjusted sales of ~$1.5bn). Exelixis has projected a peak $5bn aspirational forecast for unadjusted zanza net product revenues in 2033.
Goldman Sachs
$39.04
Buy
-2.42%
Downside
Initiated
09/17/25
H.C. Wainwright
$46
Buy
14.97%
Upside
Reiterated
09/17/25
Barclays
$40
Hold
-0.02%
Downside
Initiated
09/16/25
Citi
$56
Buy
39.97%
Upside
Reiterated
09/04/25
Exelixis's Promising Growth Potential and Strategic Expansion Justify Buy RatingWe hosted Exelixis management for a fireside chat at our Biopharma Conference, where we discussed the history of cabozantinib development, including its past, present, and future growth trajectories in its leading indication of renal cell carcinoma (RCC), where mgt estimates it currently has 25% market share in the first-line setting and 45% share in the second-line. The next chapter of growth is expected to be driven by the newly launched neuroendocrine tumor (NET) indication, which has not really yet been factored into the company’s revenue guidance raise for FY25. As for main pipeline asset zanzalintinib, which was designed as an improvement over Cabometyx, mgt continues to execute on clinical trials to bring the follow-on drug into new indications where cabo is not currently approved to avoid self-cannibalization of revenues.
TD Cowen
$44
Buy
9.97%
Upside
Reiterated
07/29/25
Guggenheim
$45
Buy
12.47%
Upside
Reiterated
07/29/25
Wells Fargo
$36
Hold
-10.02%
Downside
Reiterated
07/29/25
RBC Capital
$50→$45
Hold
12.47%
Upside
Reiterated
07/29/25
Bank of America Securities
―
Hold
―
Reiterated
07/29/25
Leerink Partners
$39→$38
Hold
-5.02%
Downside
Reiterated
07/29/25
Oppenheimer
$36
Hold
-10.02%
Downside
Reiterated
07/29/25
Best Analysts Covering Exelixis
1 Month
xxx
Success Rate
18/28 ratings generated profit
Average Return
+7.74%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 64.29% of your transactions generating a profit, with an average return of +7.74% per trade.
3 Months
xxx
Success Rate
24/28 ratings generated profit
Average Return
+24.51%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +24.51% per trade.
1 Year
Success Rate
21/24 ratings generated profit
Average Return
+23.69%
reiterated a buy rating 2 months ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +23.69% per trade.
2 Years
xxx
Success Rate
23/28 ratings generated profit
Average Return
+79.24%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 82.14% of your transactions generating a profit, with an average return of +79.24% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
EXEL Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
0
0
0
0
0
Buy
29
37
41
30
25
Hold
11
17
29
23
16
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
40
54
70
53
41
Each month's total comprises the sum of three months' worth of ratings.
EXEL Financial Forecast
EXEL Stock Forecast FAQ
What is EXEL’s average 12-month price target, according to analysts?
Based on analyst ratings, Exelixis’s 12-month average price target is 43.57.
What is EXEL’s upside potential, based on the analysts’ average price target?
Exelixis has 8.90% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is EXEL a Buy, Sell or Hold?
Exelixis has a consensus rating of Moderate Buy which is based on 10 buy ratings, 8 hold ratings and 0 sell ratings.
What is Exelixis’s price target?
The average price target for Exelixis is 43.57. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $56.00 ,the lowest forecast is $35.00. The average price target represents 8.90% Increase from the current price of $40.01.
The highest analyst price target is $56.00 ,the lowest forecast is $35.00. The average price target represents 8.90% Increase from the current price of $40.01.
What do analysts say about Exelixis?
Exelixis’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.
How can I buy shares of EXEL?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.